Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022

Rhea-AI Summary

Xencor, Inc. (NASDAQ: XNCR) announced it will release its third quarter 2022 financial results on November 7, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide an update on corporate activities. Xencor is engaged in developing engineered antibodies and cytokines to treat cancer and autoimmune diseases, with over 20 candidates in clinical trials and three marketed medicines utilizing its XmAb® technology.

Positive

• More than 20 clinical candidates are in development.
• ThreeXmAb medicines are already marketed by partners.

Negative

• None.

MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2022 financial results after the market closes on Monday, November 7, 2022.

Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.

The live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at investors.xencor.com and will be archived for at least 30 days. Active participants in the conference call may receive credentials for telephone access by registering at the following link: https://register.vevent.com/register/BIb8a7d450f24d42068f4bb86e717257fe.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb^® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005699/en/

Charles Liles

cliles@xencor.com

626-737-8118

Source: Xencor, Inc.

FAQ

When will Xencor release its Q3 2022 financial results?

Xencor will release its Q3 2022 financial results on November 7, 2022.

What time is Xencor's conference call regarding the third quarter results?

The conference call will be held at 4:30 p.m. ET on November 7, 2022.

How many clinical candidates does Xencor have?

Xencor has more than 20 clinical candidates in development.

What is XmAb technology?

XmAb technology is Xencor's engineered platform for creating antibodies and cytokines for cancer and autoimmune diseases.